CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH

Clinical trial NCT06947460 · RECRUITING

Trial details

NCT number: NCT06947460
Sponsor: Beijing GoBroad Hospital
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Refractory Lupus Nephritis Systemic Sclerosis Primary Sjogren's Syndrome Combined With Pulmonary Hypertension Other Autoimmune Diseases (AID)

Start date: 2025-04-18
Primary completion: 2026-07-31
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.